Countouriotis Athena 4

What Happened

• Athena Countouriotis, a director of Iovance Biotherapeutics (IOVA), was granted 90,316 deferred restricted stock units (DRSUs) on June 16, 2026. The award is reported as a derivative acquisition at $0.00, so there was no cash paid upfront and the immediate reported value is $0.
• Each DRSU represents a contingent right to receive one share of Iovance common stock if and when the units vest and are settled.

Key Details

• Transaction date: 2026-06-16; Form 4 filed: 2026-06-18 (appears timely).
• Grant amount: 90,316 DRSUs; price reported: $0.00 (derivative award).
• Shares owned after transaction: not specified in the filing.
• Footnotes: F1 — each DRSU converts to one common share when settled; F2 — vesting occurs on the earlier of (i) the first anniversary of the grant or (ii) the day before the issuer’s next annual shareholder meeting, provided continued service. Issuance of stock is further deferred until the earlier of (i) three months after resignation/removal or due to death/disability, (ii) a change in control, or (iii) ten years from the grant date.
• Transaction code: A = Award/Grant.

Context

• This is a compensation grant to a director, not an open-market purchase or sale; such awards are routine and do not by themselves indicate immediate insider buying or selling intent.
• Because these are deferred units, the actual issuance of shares (and any resulting ownership change) depends on future vesting and settlement events described above.